Cell adoptive cancer Immunotherapy
|
|
- Jacob Logan
- 6 years ago
- Views:
Transcription
1 SCI. Barcelona, 18/11/2016 Cell adoptive cancer Immunotherapy Daniel Benítez Ribas, PhD Dept of Immunology. Hospital Clínic Barcelona
2 Breakthrough of the year 2013 Cancer Immunotherapy
3 Specificity Block inhibitory pathways Tumor-specific T cell recognition in the periphery Lymphocyte priming to tumor antigens Only patients who have pre-existing tumor-specific T cells will benefit most from checkpoint blockade
4 Tumor immunogenicity WEAK IMMUNOGENIC STRONG IMMUNOGENIC
5 The cancer immunity cycle
6 Therapies that might affect the cancer-immunity cycle
7 Introduction The primary goal of cancer immunotherapy is to activate the immune system in cancer patients Tumors can be immunogenic Recognition of tumor antigens can lead tumor elimination Immunotherapy aiming to stimulate T lymphocytes Antigen (tumor)-specific T lymphocytes eliminate tumor Memory responses minimal residual disease (metastasis)
8 Tumor antigens Based on their molecular structure and source 1. Products of mutated oncogenes and tumor suppressor genes 2. Product of other mutated genes 3. Over expressed or aberrantly expressed cellular proteins 4. Tumor antigens produced by oncogenic viruses 5. Oncofetal antigens 6. Altered glycolipids and glycoproteins 7. Cell type-specific differentiation antigens
9 Characteristics of an ideal cancer antigen Therapeutic function Immunogenicity Oncogenicity Specificity Criteria Expression level and % positive cells Stem cell expression Top subcriteria Superb data controlled vaccines trial suggestive T-cell and/or antibody responses elicited in clinical trials Associated with oncogenic process Absolutely specific Highly expressed on all cancer cells in patients designated for treatment Evidence for expression on putative cancer stem cells Nº patients with antigen-positive cancer High level of expression in many patients with a particular tumor type Nº epitopes Longer antigen with multiple epitopes and the potential to bind to most MHC-molecules Cellular location of expression Normally expressed on the cell surface with no or little circulating antigen
10 Three ways for self antigens to become tumor antigens OJ Finn. Cancer Immunology. N Engl J Med, 2008; 358:
11 Immunostimulatory and Immunosuppressive Forces in the Tumor Microenvironment OJ Finn, Cancer Immunology. N Engl J Med, 2008; 358:
12 Therapeutic Approaches NATURE OUTLOOK. CANCER IMMUNOTHERAPY. Nature 2013, 504: 7480, S1-S16
13 Generation/induction antigen (tumor)-specific T cells Indirect (Active immunization) Cancer vaccines (tumor lysates, cells, peptides, DNA, mrna) Dendritic cells (loaded with lysates, proteins, peptides, mrna) Direct (ACT) TIL (Tumor-infiltrating lymphocytes) TCRT (TCR engineered T cells) hatcr (high affinity TCR engineered T cells) CAR-T (Chimeric antigen receptor engineered T cells)
14 Generation/induction antigen (tumor)-specific T cells Indirect (Active immunization) Cancer vaccines (tumor lysates, cells, peptides, DNA, mrna) Dendritic cells (loaded with lysates, proteins, peptides, mrna)
15 Cancer vaccine: Heterologous Melanoma cell lines vaccine Whole cell vaccine Therapeutic polivalent vaccine 1) heterogeneous expression of the cell surface antigens (melanomaassociated antigens, common surface antigens and HLA antigens) 2) balanced representatives of primary, lymph node and metastatic melanoma cells 3) heterogeneity with respect to their in vitro growth rate; and 4) absence of viral (HIV, hepatitis and HTLV), bacterial and fungal infectious organisms in the donor serum
16 Whole cell vaccine Cancer vaccine: Heterologous Melanoma cell line vaccine THERAPEUTIC POLIVALENT VACCINE PREPARATION MELANOMA CELL LINES GENERATION, SELECTION AND EXPANSION (10 cell lines) Discarded microbiological contamination Growing No production of IL-10 and TGF-b, FasL Phenotype Surgical localization MICROBIOLOGICAL TESTING MIXED OF MELANOMA LINES STORING FROZEN AT N 2
17 Vaccine Administration Whole cell vaccine THAWED IRRADIATION DNFB ADITION OF BCG INTRADERMAL INOCULATION CLOSE TO LYMPH NODES MONTHLY (FIRST YEAR), EVERY THREE MONTHS (SECOND YEAR) AND EVERY SIX MONTHS (THIRD YEAR)
18 CLINICAL RESULTS Whole cell vaccine PACIENTS AVALUABLE DISEASE: 23 RESPONSES: 6 (26%) 3 COMPLETES (18, 10+, 20+ months) 2 PARTIALS (8, 16+) 1 MIXES (30+) WITHOUT DISEASE: 15 5 (33%) STABLE (Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine. Int J Cancer 2003)
19 Complete remission of the multiple subcutaneous metastasis after 1.5 year of treatment
20 Complete remission of the multiple subcutaneous metastasis after 8 months of treatment
21 Update 10 years extension Stage MM Patients Follow up Median survival Mean survival SD Stage IIIC years 22.5 month 30.7 months 27.7 months Stage IV years 13.0 months 22.1 months 30.9 months
22 Conclusions Therapeutic vaccines It is feasible and safe to apply allogeneic tumor cells (irradiated) No side effects, the vaccine is well tolerated Inactivated whole cell vaccines have an impact in clinical responses in melanoma patients (Overall survival and complete responses) How to boost antigen (tumor) presentation?
23 Cellular response (adaptive) Natural Immune Response
24 Clinical application of DCs In human Immunogenic DCs Cancer Melanoma Colon Breast Prostate Glioma RCC HIV Tolerogenic DCs Allergy Transplantation Autoimmunity (RA)* Immune-based disorders (IMID)* MS/NMO Diabetis
25 Dendritic cell based clinical trials (2016 active) Map from clinicaltrials.gov
26 Why to use cells as therapeutic agents? Therapeutic agents Small molecules Biologics Cells Move to specific sites in the body Cells can sense diverse signals (sense surroundings) Integrate inputs to make decisions Execute complex response behaviors
27 DC clinical application. General considerations DC (modcs, circulating pdcs, mdcs, CD34 + derived) application in human patients is safe and well tolerated DCs induce Ag-specific T cells and humoral responses modifying the type of cytokines and antibody switching Some patients (tumor) develop efficient clinical responses (room for improvement and optimization)
28 Ex vivo culture of DCs. Natural DCs or their precursor cells Immature DC Growth factors Maturation factors Tumor antigens CD34+ cells Monocytes Natural DCs Apheresis Administration Clin Cancer Res; 22(8) April 15, 2016
29 DC-based therapy in stage IV melanoma patients Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell lines lysate CD14 - MHC II + CD40 +/- CD80 +/- CD83 - CD86 + IL-1b, IL-6 TNF-a, PGE 2 Tumor cell lines lysate CD14 - MHC II +++ CD40 + CD80 ++ CD83 + CD86 +++
30 DC-based therapy Clinical results 11 patients stage IV MM (post-biochemotherapy) 1 PR (partial response lasting 5 months) 2 MR 8 PD dendritic cell therapy: is well tolerated, induces an immune response shows promising antitumoral activity in stage IV melanoma patients Cancer Immunol Immunother Jul;53(7):651-8
31 DC vaccination: status After 20 years of DC vaccination: We can now induce an immune response in 40% of stage IV melanoma patients Patients with immune responses show increased progression free survival, but long-term clinical responses are still limited (25%) Objective clinical responses (5-10%) Monocyte derived DC vaccines are not yet optimal: limited survival, migration, co-stimulation, activation, Ag presentation, DC subsets Most patients treated are late stage cancer patients (2-3 line)
32 Dendritic cells in cancer immunotherapy Clinical Response Overall Survival Melanoma 8.5 % 50 % % Prostate Cancer 7.1 % 56 % % Malignant Glioma 15.6 % 49 % % Renal Carcinoma 11.5 % 108 % More than 3000 patients have been treated with DCs Data extracted from: Clinical use of dendritic cells for cancer therapy. Lancet Oncology 2014 Sébastien Anguille, Evelien L Smits, Eva Lion, Viggo F van Tendeloo, Zwi N Berneman
33 Clinical response and DTH Skin-derived specific T cells DTH 6 mm Biopsies 100 Stage III melanoma patients 100 Stage IV melanoma patients percentage specific T cells (n=24) percentage specific T cells (n=8) no specific T cells (n=7) no specific T cells (n=18) Progression free survival (months) Progression free survival (months) De Vries et al. J Clin Oncol 2005
34 Dendritic Cell Immunotherapy: Mapping the way Figdor et al Nature Med. 2004
35 Plasmacytoid DC are major type I IFN producers BDCA-2 Plasmacytoid DC Plasmacytoid DC are antigen-presenting cells. scarce (less than 0,1% of peripheral blood leukocytes). the major type I IFN producers. critical for anti-viral immunity. not yet well understood. CD123
36 DC vaccination: pdcs? Immature pdcs infiltrate solid tumors Type I IFN seems to yield more potent DCs in terms of secretion of IL- 12 and induction of tumor-specific CTLs and Th1 in vitro pdcs create the appropriate environment for efficient CTL response against viruses Activated and injected together with mdcs, pdc may improve the antitumor responses (animal models)
37 pdc: Clinical grade purification Apherese (4h) pdc isolation BDCA-4 (6h) O/N with rhil-3 (10 ng/ml) Quality control: Phenotype Purity Yield Viability TLR-ligand stimulation (6h) Peptide loading (last 2h) Injection (intranodal) Quality control: Phenotype IFN-α production T cell stimulation Prophylactic vaccines mimic synthetic CpG oligonucleotides in their ability to modulate immune responses. Mol Immunol Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells. Blood, 2010
38 Schematic overview of the pdc culture protocol and vaccination strategy. Jurjen Tel et al. Cancer Res 2013;73: by American Association for Cancer Research
39 Activated pdcs are mature and migrate to distinct lymph nodes in vivo. Jurjen Tel et al. Cancer Res 2013;73: by American Association for Cancer Research
40 pdcs induce immune responses to FSME in vivo T cell responses FSME specific T cell response ns Humoral responses FSME - IgG in Blood T cell Proliferation - CPM Arbitrary units (U/ml) ns *** Before vacc. After 3 vacc. 0 Before Vacc. After 1 Vacc. After 2 Vacc. After 3 Vacc. Frühsommer-Meningoenzephalitis (FSME; tick-borne encephalitis) activates pdcs via TLR9 and TLR7
41 Tumor specific T-cells in 8 vaccinated patients DTH MLPC Tetramer APC gp gp tyrosinase gp100 tyrosinase 0.4 % 0.2 % 0.2 % 0.1 % 0.3 % 0.4 % Frequency of antigen specific CD3 + CD8 + T cells gp gp tyrosinase ** ns ns CD8 FITC
42 pdc vaccination improves OS Clinical outcome to pdc vaccination was compared with a group of carefully matched historical control patients who received dacarbazine as first-line treatment Jurjen Tel et al. Cancer Res 2013;73: by American Association for Cancer Research
43 Clinical outcome after vaccination with pdc Overall survival stage IV melanoma patients Percent survival pdc (n=15) P= year survival: - historical matched controls 35 % - pdc group 60% 2-year survival: - historical matched controls 10 % - pdc group 45% matched controls (n=72) Overall survival (months) Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res Feb ;73(3)
44 Conclusions Human pdc can be isolated and stimulated according to GMP FSME is a good substitute for CpG-C to trigger pdc via TLR, IFN-α, migration in vitro and in vivo, Ag presentation Commonly used vaccines are safe, good and cheap substitutes for synthetic GMP TLR ligands Clinical trials with peptide-loaded pdc are feasible (natural circulating DCs) No severe side effects nor toxicity has been observed pdc vaccine increase OS in stage IV melanoma patients
45 NATURE OUTLOOK. CANCER IMMUNOTHERAPY. Nature 2013, 504: 7480, S1-S16 OUTLOOK: SEARCHING FOR SYNERGY 1. Potentiate Ag-specific T cells 2. Block checkpoints inhibitors 3. Block immunosuppressive tumors environment
46 Therapeutic neoantigen-based vaccination Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother Apr 8. Westdorp H, et al.
47 Therapeutic approach for Lynch syndrome Opportunities for immunotherapy in microsatellite instable colorectal cancer. Cancer Immunol Immunother Apr 8. Westdorp H, et al.
48 Clinical trials ongoing (based on DC) Hospital Clinic de Barcelona Protocol PEI NCT Eudra-CT Crohn intralesional NCT MS * /NMO * NCT CCR * NCT DIPG * -DC NCT CCR * + Avelumab MS/NMO: multiple sclerosis; neuromielitis optica, CCR: colorectal cancer, DIPG: difuse pontine glioma DCs Phase II randomized trial of autologous tumour lysate dendritic cell (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced CRC patients colon. Eur J Cancer Sep;64:
49 Take home message Cancer immunotherapies can eradicate tumours leading to complete and durable responses
50 Acknowledgements Hospital Clínic de Barcelona Department of Immunology NCMSL. Radboud University Department of Tumor Immunology TSF/BST (Transplant Service Foundation) Dept. Dermatology Radiology Surgery Microbiology Medical oncology Hematology
51
52 DCs Phase II randomized trial of autologous tumour lysate dendritic cell (ADC) plus best supportive care (BSC) compared with BSC, in pre-treated advanced CRC patients colon
53 61 patients assessed for eligibility 9 patients excluded 8 did not meet the inclusion criteria 6 positive virus (VIH, HBV) 2 no biopsiable disease 1 declined to participate 52 patients randomized ITT population 28 patients allocated to ADC+BSC 24 patients allocated to BSC 1 patient did not initiate treatment 27 patients received treatment 8 patients received potential active treatment+bsc 16 patients received BSC only
54 No clinical benefit PFS Progression-free survival (%) BSC ADC + BSC Days after randomization OS Overall Survival (%) BSC ADC + BSC Days after randomization
55 DC expands/induce tumor specific T-cells p=0, CPM p<0,0001 % cells Th1 (Ifn-g +) p<0, PRE POST 40 POST 120 PRE POST 40 POST 120
56 OS is increased in patients with Ag-specific T cells Overall Survival (%) OS p<0,02 ATMLR increase Non-ATMLR increase Days after randomization
57 Exogenous Ag presentation The poor ability to induce specific CD4+ T cell responses against exogenous antigens has been correlated with the lack of protein uptake by pdcs AIM To study the capacity of human pdcs to take up and present exogenous antigen
58 Vaccination protocol: monocyte-derived DC IL-4 GM-CSF KLH immature DC Maturation peptides monocytes mature DC - Metastatic melanoma - HLA-A gp100 + tyrosinase + KLH specific T cells (PBMC) KLH specific antibodies (post-vacc serum)
59 pdcs are able to present KLH. Specific T cell proliferation Humoral response to KLH No humoral response to KLH KLH-Alexa KLH-Alexa 3 H incorporation (cpm * 10 4 ) 3 H incorporation (cpm * 10 4 ) * ** 1/20 1/100 pdc/pbl ratio 1/20 1/100 control KLH J Exp Med Jul 10;203(7):1629
60 Endocytic receptors on freshly isolated pdcs CD32a DEC 205 CD36 BDCA-2 MHC class I DC-SIGN MR DCIR Dectin-1 Isotype DEC-205 mediates antigen uptake and presentation by both resting and activated human plasmacytoid dendritic cells. Eur J. Immunol 2011 Targeting DCIR on human plasmacytoid dendritic cells results in antigen presentation and inhibits IFN-α production. Blood. 2008
61 pdcs take up exogenous antigen Magnetic isolation BDCA-4 beads Purity (>95%) BDCA-2 pdcs from blood of: Normal donor Non-vaccinated 1.5 % Mono-DC (KLH) Vaccinated patients 36 % CD123 Specific antibodies against KLH KLH-Alexa NO NO YES
62 pdcs are able to take up KLH (immune complexes post-vaccination serum dependent) pdcs from normal donors + Serum from same patient (before/after vaccination) 1 % serum 5 % serum 20 % serum 23 % 55 % 58 % Before vaccination After vaccination KLH-Alexa 488 Are FcR involved?
63 KLH uptake is mediated by FcγRII/CD32 CD32a expression KLH-Alexa 48 % Irrelevant protein 5 % Isotype + KLH-Alexa Anti-CD32 + KLH-Alexa 45 % 20 % Are pdcs able to process and present KLH to specific T cells?
64 Blockade of PD-1 or CTLA-4 Signaling in Tumor Immunotherapy Antoni Ribas. Tumor Immunotherapy Directed at PD-1. N Engl J Med, ;26
65 Checkpoints inhibitors and new therapeutic opportunities CTLA-4 PD-1 New therapeutic approaches Anti-CTLA-4 Hard wired Targets CD28 pathway Expands clonal diversity Can move T cells into tumor Disease recurrence after response is rare Anti-PD-1 Induce resistance Targets TCR pathway Does not expand clonal diversity Does not move T cells into tumors Disease recurrence after response is significant
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use
Developing Novel Immunotherapeutic Cancer Treatments for Clinical Use Oncology for Scientists March 8 th, 2016 Jason Muhitch, PhD Assistant Professor Department of Urology Email: jason.muhitch@roswellpark.org
More information08/02/59. Tumor Immunotherapy. Development of Tumor Vaccines. Types of Tumor Vaccines. Immunotherapy w/ Cytokine Gene-Transfected Tumor Cells
Tumor Immunotherapy Autologous virus Inactivation Inactivated virus Lymphopheresis Culture? Monocyte s Dendritic cells Immunization Autologous vaccine Development of Tumor Vaccines Types of Tumor Vaccines
More informationIMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust
IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent
More informationDeterminants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco
Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?
More informationTumors arise from accumulated genetic mutations. Tumor Immunology (Cancer)
Tumor Immunology (Cancer) Tumors arise from accumulated genetic mutations Robert Beatty MCB150 Mutations Usually have >6 mutations in both activation/growth factors and tumor suppressor genes. Types of
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationT-cell activation T cells migrate to secondary lymphoid tissues where they interact with antigen, antigen-presenting cells, and other lymphocytes:
Interactions between innate immunity & adaptive immunity What happens to T cells after they leave the thymus? Naïve T cells exit the thymus and enter the bloodstream. If they remain in the bloodstream,
More informationDendritic Cell Based Immunotherapy for Cancer. Edgar G. Engleman, M.D.
Dendritic Cell Based Immunotherapy for Cancer Edgar G. Engleman, M.D. Two main DC subsets Myeloid (mydc) Derived from monocytes Capture/process/present Ag to T cells Activate NK cells and B cells Plasmacytoid
More informationRadboud Institute for Molecular Life Sciences. Tumor Antigen-loaded Natural Dendritic Cells: A More Powerful Next Generation cancer vaccine?
Radboud Institute for Molecular Life Sciences Tumor Antigen-loaded Natural Dendritic Cells: A More Powerful Next Generation cancer vaccine? I. Jolanda M. de Vries Department of Tumor Immunology and Medical
More informationReleasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies
Releasing the Brakes on Tumor Immunity: Immune Checkpoint Blockade Strategies Jason Muhitch, PhD MIR 509 October 1 st, 2014 Email: jason.muhitch@roswellpark.org 0 Holy Grail of Tumor Immunity Exquisite
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 1 October 2016 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Immunology in the CNS
More informationTumor Immunology. Wirsma Arif Harahap Surgical Oncology Consultant
Tumor Immunology Wirsma Arif Harahap Surgical Oncology Consultant 1) Immune responses that develop to cancer cells 2) Escape of cancer cells 3) Therapies: clinical and experimental Cancer cells can be
More informationImmune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich
Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3
More informationDISCLOSURES. Roche/MSD-Merck/Celgene: Research Funding
DISCLOSURES Roche/MSD-Merck/Celgene: Research Funding Roche/Celgene/AstraZeneca/Amgen/MSD/Novartis/Sanofi- Aventis/Pierre Fabré: Advisory Board or Consultant No conflict of interest with respect to this
More informationSummary... 2 IMMUNOTHERAPY IN CANCER... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 IMMUNOTHERAPY IN CANCER... 3 Sequencing analysis reveals baseline tumour T cell receptor and neo antigen load associates
More informationTumor Immunity and Immunotherapy. Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School
Tumor Immunity and Immunotherapy Andrew Lichtman M.D., Ph.D. Brigham and Women s Hospital Harvard Medical School Lecture Outline Evidence for tumor immunity Types of tumor antigens Generation of anti-tumor
More informationUpdate on cell therapy using dendritic cells
Update on cell therapy using dendritic cells Prof. dr. Evelien Smits UAntwerp, 24 March 2017 evelien.smits@uza.be Hallmarks of cancer (Hanahan and Weinberg, Cell 2000) Hanahan and Weinberg, 2000 Extra
More informationImmunotherapy for the Treatment of Cancer
Immunotherapy for the Treatment of Cancer Jason Muhitch, PhD Assistant Professor Department of Urology Department of Immunology Roswell Park Comprehensive Cancer Center Oncology for Scientists March 15,
More informationImmunology Lecture 4. Clinical Relevance of the Immune System
Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor
More informationImmune surveillance hypothesis (Macfarlane Burnet, 1950s)
TUMOR-IMMUNITÄT A.K. Abbas, A.H. Lichtman, S. Pillai (6th edition, 2007) Cellular and Molecular Immunology Saunders Elsevier Chapter 17, immunity to tumors Immune surveillance hypothesis (Macfarlane Burnet,
More informationImmunotherapie: algemene principes
Immunotherapie: algemene principes Prof. dr. Evelien Smits Tumorimmunologie, UAntwerpen 14 Oktober 2017, IKG evelien.smits@uza.be Concept of immune evasion Finn O. J. Ann Oncol. 2012 Sep; 23(Suppl 8):
More informationCOURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16
COURSE: Medical Microbiology, PAMB 650/720 - Fall 2008 Lecture 16 Tumor Immunology M. Nagarkatti Teaching Objectives: Introduction to Cancer Immunology Know the antigens expressed by cancer cells Understand
More information2/16/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
C007: Immunology of Melanoma: Mechanisms of Immune Therapies Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los Angeles Biomedical
More informationGlioblastoma and CNS tumors
Glioblastoma and CNS tumors PRECEPTORSHIP PROGRAMME IMMUNO-ONCOLOGY Amsterdam, 27 May 2017 Patrick Roth Department of Neurology and Brain Tumor Center University Hospital Zurich Challenges in immunooncology
More informationEngineered Immune Cells for Cancer Therapy : Current Status and Prospects
When Engineering Meets Immunology Engineered Immune Cells for Cancer Therapy : Current Status and Prospects Yong Taik Lim, Ph.D. Nanomedical Systems Laboratory (http://www.nanomedicalsystems.org) SKKU
More informationAntigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS
1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family
More informationLecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells
1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:
More informationCancer immunity and immunotherapy. General principles
1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or
More informationGeneral Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center
General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses
More informationImmune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment
Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu HSL GeneticEpi Center,
More informationBasic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression. Bryon Johnson, PhD
Basic Principles of Tumor Immunotherapy and Mechanisms of Tumor Immune Suppression Bryon Johnson, PhD Disclosures There will be discussion about the use of products for non-fda indications in this presentation.
More informationPriming the Immune System to Kill Cancer and Reverse Tolerance. Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics
Priming the Immune System to Kill Cancer and Reverse Tolerance Dr. Diwakar Davar Assistant Professor, Melanoma and Phase I Therapeutics Learning Objectives Describe the role of the immune system in cancer
More informationCancer Immunotherapy: Active Immunization Approaches
Cancer Immunotherapy: Active Immunization Approaches Willem W. Overwijk, PhD Department of Melanoma Medical Oncology MD Anderson Cancer Center Houston, TX, USA Disclosures No relevant financial relationships
More informationEmerging Targets in Immunotherapy
Emerging Targets in Immunotherapy So Jin Shin, M.D. Department of Obstetrics and Gynecology, Keimyung University, School of Medicine, Daegu, Korea no-0ncology Todays is.. ancer Immunotherapy? nd immunotherapy
More informationImmuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017
Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY
More informationProfessor Mark Bower Chelsea and Westminster Hospital, London
Professor Mark Bower Chelsea and Westminster Hospital, London Cancer immunotherapy & HIV Disclosures: None Lessons for oncology from HIV Awareness and advocacy Activism Rational drug design Prescribing
More informationImmunological Tolerance
Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for
More informationLAG-3: Validation Of Next Generation Checkpoint Pathways
LAG-3: Validation Of Next Generation Checkpoint Pathways Frédéric Triebel, CO/CMO Immune Checkpoint Modulation & Combination Therapies April 13, 2016 London, UK. 1 AX:PRR; NADAQ:PBMD Notice: Forward Looking
More informationT Lymphocyte Activation and Costimulation. FOCiS. Lecture outline
1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 11 T-Cell Activation, Differentiation, and Memory Copyright 2013 by W. H. Freeman and
More informationImmuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning
Immuno-Oncology Therapies and Precision Medicine: Personal Tumor-Specific Neoantigen Prediction by Machine Learning Yi-Hsiang Hsu, MD, SCD Sep 16, 2017 yihsianghsu@hsl.harvard.edu Director & Associate
More information2/19/2018. The Immune System and Cancer. Fatal Melanoma Transferred in a Donated Kidney 16 years after Melanoma Surgery
F141: Advanced Melanoma: Mechanisms of Immune Therapies beyond Checkpoint blockade Delphine J. Lee, MD, PhD Chief and Program Director, Dermatology, Harbor UCLA Medical Center Principal Investigator, Los
More informationDendritic cell vaccinations and optimal antigen presentation
Dendritic cell vaccinations and optimal antigen presentation Thierry Noorbergen (3384578) Master Infection & Immunity, Universiteit Utrecht UMC Utrecht, Department of Clinical Chemistry and Haematology,
More informationSynergistic combinations of targeted immunotherapy to combat cancer
Synergistic combinations of targeted immunotherapy to combat cancer Myung Ah Lee, M.D., Ph. D Division of Medical Oncology, Hepato-biliary pancreatic cancer center Seoul St. Mary s hospital, The Catholic
More informationBasic Principles of Tumor Immunotherapy. Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA
Basic Principles of Tumor Immunotherapy Ryan J. Sullivan, M.D. Massachusetts General Hospital Cancer Center Boston, MA Disclosures Consulting Fees: Biodesix, Novartis Pharmaceuticals Other: Boehringer
More informationExploring Immunotherapies: Beyond Checkpoint Inhibitors
Exploring Immunotherapies: Beyond Checkpoint Inhibitors Authored by: Jennifer Dolan Fox, PhD VirtualScopics (Now part of BioTelemetry Research) jennifer_fox@virtualscopics.com +1 585 249 6231 Introduction
More information5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x)
Immune surveillance 5% of patients with genetic immunodeficiency develop a cancer during their lifetime (200x) Transplanted patients following an immunosuppressor therapy are 80 times more likely to develop
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Cervix
More informationThe PD-1 pathway of T cell exhaustion
The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1
More informationCBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology
CBER Regulatory Considerations for Clinical Development of Immunotherapies in Oncology Peter Bross, MD Office of Cellular, Tissue and Gene Therapies, CBER FDA IOM Policy Issues in the Clinical Development
More informationEffector T Cells and
1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New
More informationTHE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER
Gynecologic Cancer InterGroup Cervix Cancer Research Network THE ROLE OF TARGETED THERAPY AND IMMUNOTHERAPY IN THE TREATMENT OF ADVANCED CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum
More informationLecture 9: T-cell Mediated Immunity
Lecture 9: T-cell Mediated Immunity Questions to Consider How do T cells know where to go? Questions to Consider How do T cells know where to go? How does antigen get targeted to a T cell expressing the
More informationPersonalized medicine - cancer immunotherapy
Personalized medicine - cancer immunotherapy Özcan Met, PhD Senior Staff Scientist, Cell Therapy Director Center for Cancer Immune Therapy Department of Hematology Department of Oncology University Hospital
More informationThe Adaptive Immune Responses
The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start
More informationTCR, MHC and coreceptors
Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed
More informationInnovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014
Innovation in Prevention, Early Detection & Diagnosis of Colorectal Cancer Heidelberg Workshop Session VI, Oncology Pipeline June 6, 2014 Bernd Mueller MSD Sharp & Dohme, Germany Normal Immune Surveillance:
More informationImmunotherapy: The Newest Treatment Route
Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William
More informationScott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION
Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.
More informationTumor Immunology. Tumor (latin) = swelling
Tumor Immunology Tumor (latin) = swelling benign tumor malignant tumor Tumor immunology : the study of the types of antigens that are expressed by tumors how the immune system recognizes and responds to
More informationThe Immune System. Innate. Adaptive. - skin, mucosal barriers - complement - neutrophils, NK cells, mast cells, basophils, eosinophils
Objectives - explain the rationale behind cellular adoptive immunotherapy - describe methods of improving cellular adoptive immunotherapy - identify mechanisms of tumor escape from cellular adoptive immunotherapy
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationTolerance 2. Regulatory T cells; why tolerance fails. Abul K. Abbas UCSF. FOCiS
1 Tolerance 2. Regulatory T cells; why tolerance fails Abul K. Abbas UCSF FOCiS 2 Lecture outline Regulatory T cells: functions and clinical relevance Pathogenesis of autoimmunity: why selftolerance fails
More informationIris Bigalke ISCT Europe 2015 Regional Meeting
Vaccination with a new generation of tumorspecific mrna loaded dendritic cells prolong progression free survival in patients with different types of malignancies Iris Bigalke 25.09.2015 ISCT Europe 2015
More informationVISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School
VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:
More informationM.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology
Code : AS-2246 M.Sc. III Semester Biotechnology End Semester Examination, 2013 Model Answer LBTM: 302 Advanced Immunology A. Select one correct option for each of the following questions:- 2X10=10 1. (b)
More informationRadiation Therapy as an Immunomodulator
Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination
More informationOncolytic Immunotherapy: A Local and Systemic Antitumor Approach
Oncolytic Immunotherapy: A Local and Systemic Antitumor Approach Oncolytic immunotherapy Oncolytic immunotherapy the use of a genetically modified virus to attack tumors and induce a systemic immune response
More informationEndogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade
Endogenous and Exogenous Vaccination in the Context of Immunologic Checkpoint Blockade Jedd Wolchok Ludwig Center for Cancer Immunotherapy Memorial Sloan-Kettering Cancer Center MEMORIAL SLOAN- KETTERING
More informationImmunotherapy for dmmr metastatic colorectal cancer. Prof.dr. Kees Punt Dept. Medical Oncology AUMC
Immunotherapy for dmmr metastatic colorectal cancer Prof.dr. Kees Punt Dept. Medical Oncology AUMC Active specific immunotherapy (ASI) in stage II-III colon cancer Vaccination with autologous tumor + BCG
More informationLiver Cancer. Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine
Liver Cancer Su Jong Yu, M.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Primary Liver Cancer Hepatocellular carcinoma (HCC) : > 80% Derived
More informationImmunotherapy in Colorectal cancer
Immunotherapy in Colorectal cancer Ahmed Zakari, MD Associate Professor University of Central Florida, College of Medicine Medical Director, Gastro Intestinal Cancer Program Florida Hospital Cancer Institute
More informationFocus on Immunotherapy as a Targeted Therapy. Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct
Focus on Immunotherapy as a Targeted Therapy Brad Nelson, PhD BC Cancer, Victoria, Canada FPON, Oct 18 2018 Disclosures I have nothing to disclose that is relevant to this presentation. Immunology @ Deeley
More informationFOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1
1 Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF FOCiS 2 Lecture outline Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory
More informationIs Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015
Is Prostate Cancer Amenable to Immunotherapy Approaches? New Frontiers in Urologic Oncology, September 12, 2015 J. J. Mulé Associate Center Director, Translational Research U.S. Senator Connie Mack & Family
More informationRegulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D.
Regulation of anti-tumor immunity through migration of immune cell subsets within the tumor microenvironment Thomas F. Gajewski, M.D., Ph.D. Professor, Departments of Pathology and Medicine Program Leader,
More informationACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT
ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes
More informationEmerging Tissue and Serum Markers
Emerging Tissue and Serum Markers for Immune Checkpoint Inhibitors Kyong Hwa Park MD, PhD Medical Oncology Korea University College of Medicine Contents Immune checkpoint inhibitors in clinical practice
More informationEmerging Concepts of Cancer Immunotherapy
Emerging Concepts of Cancer Immunotherapy Jeffrey Schlom, Ph.D. Laboratory of Tumor Immunology and Biology (LTIB) Center for Cancer Research National Cancer Institute, NIH Immune Cell Infiltrate in Primary
More informationTumor responses (patients responding/ patients treated)
Table 1. ACT clinical trial tumor responses and toxicities. a Target antigen Cancer(s) Receptor type Tumor responses (patients responding/ patients treated) Immune-mediated toxicities (patients experiencing
More informationThird line of Defense
Chapter 15 Specific Immunity and Immunization Topics -3 rd of Defense - B cells - T cells - Specific Immunities Third line of Defense Specific immunity is a complex interaction of immune cells (leukocytes)
More informationImmunotherapy of HNC: immune mechanisms and therapeutic targets
Immunotherapy of HNC: immune mechanisms and therapeutic targets Ourania Tsitsilonis, MD, PhD Department of Biology National & Kapodistrian University of Athens What does the Immune System see in Cancer?
More informationThe next steps for effective cancer immunotherapy and viral vaccines. Peter Selby FACP(UK)
The next steps for effective cancer immunotherapy and viral vaccines Peter Selby FACP(UK) Richard Alan Steve Sasha Matt Nav Vile Melcher Griffin Zougman Bentham Vasudev Adel Nick Gemma Liz Samson Hornigold
More informationTherapeutic efficacy of MUC1- specific CTL and CD137 costimulation. mammary cancer model. Pinku Mukherjee & Sandra Gendler
Therapeutic efficacy of MUC1- specific CTL and CD137 costimulation in a spontaneous mammary cancer model Pinku Mukherjee & Sandra Gendler Goal of Immunotherapy Boosting the low level anti-tumor immune
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationDEVELOPMENT OF CELLULAR IMMUNOLOGY
DEVELOPMENT OF CELLULAR IMMUNOLOGY 1880 s: Antibodies described (dominated studies of immunology until 1960 s) 1958: Journal of Immunology (137 papers) lymphocyte not listed in index Two papers on transfer
More informationCancer Immunotherapy Survey
CHAPTER 8: Cancer Immunotherapy Survey All (N=100) Please classify your organization. Academic lab or center Small biopharmaceutical company Top 20 Pharma Mid-size pharma Diagnostics company Other (please
More informationCONTRACTING ORGANIZATION: Johns Hopkins University School of Medicine Baltimore, MD 21205
AD Award Number: DAMD7---7 TITLE: Development of Artificial Antigen Presenting Cells for Prostate Cancer Immunotherapy PRINCIPAL INVESTIGATOR: Jonathan P. Schneck, M.D., Ph.D. Mathias Oelke, Ph.D. CONTRACTING
More informationCancer Vaccines and Cytokines. Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology
Cancer Vaccines and Cytokines Elizabeth A. Mittendorf, MD, PhD Assistant Professor Department of Surgical Oncology Disclosures I serve as the PI on a phase III trial sponsored by Galena BioPharma investigating
More informationEffector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells
ICI Basic Immunology course Effector mechanisms of cell-mediated immunity: Properties of effector, memory and regulatory T cells Abul K. Abbas, MD UCSF Stages in the development of T cell responses: induction
More informationDendritic cells in cancer immunotherapy Aimin Jiang
Dendritic cells in cancer immunotherapy Aimin Jiang Feb. 11, 2014 Dendritic cells at the interface of innate and adaptive immune responses Dendritic cells: initiators of adaptive immune responses Dendritic
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationTransforming science into medicine
Transforming science into medicine 2 Forward-looking statements This presentation contains forward-looking statements. These statements include words like may, expects, believes, plans, scheduled, and
More informationCANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University
CANCER IMMUNOPATHOLOGY Eryati Darwin Faculty of Medicine Andalas University Padang 18 Mei 2013 INTRODUCTION Tumor: cells that continue to replicate, fail to differentiate into specialized cells, and become
More informationImmunity and Cancer. Doriana Fruci. Lab di Immuno-Oncologia
Immunity and Cancer Doriana Fruci Lab di Immuno-Oncologia Immune System is a network of cells, tissues and organs that work together to defend the body against attacks of foreign invaders (pathogens, cancer
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationIMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER. Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia
IMMUNOTHERAPY IN THE TREATMENT OF CERVIX CANCER Linda Mileshkin, Medical Oncologist Peter MacCallum Cancer Centre, Melbourne Australia Distinguishing self from non-self T cells trained in the thymus as
More informationNovel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates
Novel RCC Targets from Immuno-Oncology and Antibody-Drug Conjugates Christopher Turner, MD Vice President, Clinical Science 04 November 2016 Uveal Melanoma Celldex Pipeline CANDIDATE INDICATION Preclinical
More information